What does Fore Biotherapeutics do?
Fore Biotherapeutics is a biotherapeutics company focused on developing targeted therapies to treat hard-to-treat cancers. The company leverages innovative approaches, including its lead asset plixorafenib, to address treatment gaps left by earlier generation BRAF inhibitors.
How much did they raise?
The company secured $38M in Series D-2 financing with lead investment from firms such as R One, Medicxi, OrbiMed, HBM Healthcare Investments, Wellington Management, Novartis Venture Fund, Cormorant Asset Management, and 3B Future Health Fund. This round adds to previous Series D financings totaling $75M, bringing the aggregate Series D funding to $113M.
What are their plans for the money?
The funds are earmarked to advance the registration-intended Forte Master Protocol, a global Phase 2 clinical trial that includes four sub-protocol baskets for evaluating plixorafenib in distinct patient populations. This strategic investment could accelerate the drug's development and expand treatment options for patients with difficult-to-treat cancers.
What have they achieved so far?
Fore Biotherapeutics has already demonstrated promising single-agent efficacy signals and a manageable safety profile in a Phase 1/2a trial involving over 100 patients. The ongoing enrollment in the FORTE basket trial further highlights the company’s commitment to delivering new therapies for advanced cancer.
